Damora Therapeutics (DMRA) Short-term Investments (2021 - 2024)

Damora Therapeutics' Short-term Investments history runs 4 years deep, the most recent figure standing at $6.1 million for Q1 2024.

• Quarterly Short-term Investments fell 78.42% year-over-year to $6.1 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $6.1 million (down 78.42% YoY) and the FY2023 annual result came in at $11.7 million, down 57.41% from the prior year.
• Short-term Investments was $6.1 million for Q1 2024 at Damora Therapeutics, down from $11.7 million in the prior quarter.
• Across five years, Short-term Investments topped out at $49.2 million in Q2 2022 and bottomed at $6.1 million in Q1 2024.
• A 4-year average of $31.1 million and a median of $33.2 million in 2021 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments jumped 48.39% — and 2024, when it tumbled 78.42%.
• Damora Therapeutics' Short-term Investments stood at $37.6 million in 2021, then retreated by 27.08% to $27.4 million in 2022, then plunged by 57.41% to $11.7 million in 2023, then tumbled by 47.97% to $6.1 million in 2024.
• Business Quant data shows DMRA's Short-term Investments at $6.1 million in Q1 2024, $11.7 million in Q4 2023, and $21.1 million in Q3 2023.